Advertisement
Screener

AGENUS INC (AGEN) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

2.0 / 5 stars · 38/94 Roast Me

Add as a preferred source on Google

AGENUS INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

AGENUS INC (AGEN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.89 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-07

  • AGENUS INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.02, a 0.66% decline year-over-year.
  • AGENUS INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.04, a 82.57% decline year-over-year.
  • AGENUS INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $17.44, a 620.66% increase year-over-year.
  • AGENUS INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.42, a 22.19% decline year-over-year.
  • AGENUS INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.25, a 52.97% decline from fiscal 2024.
  • AGENUS INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.91, a 211.26% increase from fiscal 2023.
  • AGENUS INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.22, a 24.23% decline from fiscal 2022.
  • AGENUS INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.93, a 18.16% decline from fiscal 2021.
Period endShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month
2026-06-30$3.89
10-Q · filed 2026-08-07
2026-03-31$3.02
10-Q · filed 2026-05-11
2025-12-31$3.25
10-K · filed 2026-03-16
2025-09-30$3.22
10-Q · filed 2025-11-10
2025-06-30$3.05
10-Q · filed 2025-08-11
2025-03-31$3.04
10-Q · filed 2025-05-12
2024-12-31$6.91
10-K · filed 2025-03-17
2024-09-30$12.81
10-Q · filed 2024-11-12
2024-06-30$12.87
10-Q · filed 2024-08-08
2024-03-31$17.44
10-Q · filed 2024-05-07
2023-12-31$2.22
10-K · filed 2024-03-14
2023-09-30$2.26
10-Q · filed 2023-11-09
2023-06-30$2.35
10-Q · filed 2023-08-08
2023-03-31$2.42
10-Q · filed 2023-05-09
2022-12-31$2.93
10-K · filed 2023-03-16
2022-09-30$2.95
10-Q · filed 2022-11-08
2022-06-30$3.00
10-Q · filed 2022-08-09
2022-03-31$3.11
10-Q · filed 2022-05-10
2021-12-31$3.58
10-K · filed 2022-03-01
2021-09-30$3.52
10-Q · filed 2021-11-09
2021-06-30$3.38
10-Q · filed 2021-08-09
2021-03-31$3.67
10-Q · filed 2021-05-07
2020-12-31$3.82
10-K · filed 2021-03-16
2020-09-30$4.00
10-Q · filed 2020-11-09
2020-06-30$4.01
10-Q · filed 2020-08-10
2020-03-31$3.53
10-Q · filed 2020-05-11
2019-12-31$3.00
10-K · filed 2020-03-16
2019-09-30$2.42
10-Q · filed 2019-11-07
2019-06-30$2.41
10-Q · filed 2019-08-09
2019-03-31$3.10
10-Q · filed 2019-05-10
2018-12-31$4.06
10-K · filed 2019-03-18
2018-09-30$5.21
10-Q · filed 2018-11-07
2018-06-30$5.46
10-Q · filed 2018-08-09
2018-03-31$4.20
10-Q · filed 2018-05-10
2017-12-31$3.81
10-K · filed 2018-03-16
2017-09-30$3.80
10-Q · filed 2017-11-07
2017-06-30$3.78
10-Q · filed 2017-08-07
2017-03-31$3.78
10-Q · filed 2017-05-04
2016-12-31$4.28
10-K · filed 2017-03-16
2016-09-30$4.26
10-Q · filed 2016-11-09
2016-06-30$4.13
10-Q · filed 2016-08-04
2016-03-31$4.18
10-Q · filed 2016-05-09
2015-12-31$5.82
10-K · filed 2016-03-15
2015-09-30$5.93
10-Q · filed 2015-11-04
2015-06-30$5.40
10-Q · filed 2015-08-03
2015-03-31$4.94
10-Q · filed 2015-05-01
2014-12-31$3.02
10-K · filed 2015-03-16
2014-09-30$3.02
10-Q · filed 2014-10-31
2014-06-30$3.01
10-Q · filed 2014-08-01
2014-03-31$3.27
10-Q · filed 2014-05-09
2013-12-31$3.40
10-K · filed 2014-03-07
2013-09-30$3.41
10-Q · filed 2013-11-08
2013-06-30$3.70
10-Q · filed 2013-08-09
2013-03-31$4.16
10-Q · filed 2013-05-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
Surrozen, Inc./DE (SRZN)United States$0.395B
Zura Bio Ltd (ZURA)$0.398B-6.56
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Ocugen, Inc. (OCGN)United States$0.343B-6.34
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Advertisement